OUR TECHNOLOGY
Overview
Autoimmune disease occurs when the immune system mistakenly targets the body’s own healthy cells and tissue, causing inflammation and organ damage. The National Institutes of Health estimates that 23.5 million Americans suffer from at least one of 80 different autoimmune disorders, frequently with severe or life-threatening health consequences.
Although the precise mechanisms that trigger autoimmunity have not been fully explained, it is known that a dysregulation in T cells is a key component, given their critical role in immunosurveillance. Overcoming the limitations of current treatment methods for autoimmune disease will require a fundamentally different approach that targets the T cells driving specific immune responses.
TCR Biotherapeutics is developing a technology based on the immunomodulatory potential of modified T cell receptors (TCRs) in addressing multiple autoimmune diseases and graft vs. host disease (GVHD), a potential complication of allogeneic hematopoietic cell transplantation. The advantages of our platform is that it can be scaled or tailored across multiple dimensions: breadth, complexity, composition and in combination with other therapies.
Target Indications:
Initial Product Candidate
TCR001 Inhibits T Cell Activation
TCR001 is a first-in-class immunotherapy that interferes with T cell activation by masking the peptide-major histocompatibility complex (pMHC) and preventing TCR engagement. TCR001 is designed to avoid the potential adverse side effects of current immunosuppressive therapies, supporting a safer treatment.
